Pliant Therapeutics announces FDA clearance of IND application for PLN-101095

Pliant Therapeutics announced that the U.S. Food and Drug Administration, FDA, has cleared the company’s Investigational New Drug, IND, application for PLN-101095, an oral, small molecule, dual selective inhibitor of integrins alphavbeta8 and alphavbeta1. A Phase 1 first-in-human study evaluating PLN-101095 in patients with solid tumors that are resistant to immune checkpoint inhibitors, ICIs, is expected to initiate in the second quarter of 2023. "PLN-101095 represents our third program to advance into clinical development, this time targeting significant unmet need of cancer patients with a suboptimal response to immune checkpoint inhibitors," said Eric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. "Based on the compelling preclinical activity seen in tumor models with PLN-101095 in combination with immune checkpoint inhibitors, we look forward to evaluating this combination in patients with solid tumors."